Clinical Trial

Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE

Name: Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE — clinical trial record (NCT06934447)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-BCMA/CD70 CAR-T cells in the treatment of refractory systemic lupus erythematosus.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-04-11.

Trial Details

NCT Number	NCT06934447
Lead Sponsor	The Children's Hospital of Zhejiang University School of Medicine Collaborators: Chongqing Precision Biotech Co., Ltd
Conditions	CAR T Cell Therapy, Systemic Lupus Erythematosus, BCMA
Enrollment	18 participants
Start Date	2025-04-25
Primary Completion	2028-04-01 (estimated)
Study Completion	2028-04-01 (estimated)
Updated on ClinicalTrials.gov	2025-04-25